InMed Pharmaceuticals Inc（INM）财务数据INMInMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc (INM) generates its revenue primarily from BayMedica, which accounts for 100.0% of total sales, equivalent to $1.30M. Understanding this concentration is critical for investors evaluating how INM navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, InMed Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -112.65%, provide a clear picture of how effectively INM converts its operational activities into shareholder value.

In the context of the broader market, INM competes directly with industry leaders such as SBFM and GLMD. With a market capitalization of $7.80M, it holds a leading position in the sector. When comparing efficiency, INM's gross margin of N/A stands against SBFM's 25.35% and GLMD's N/A. Such benchmarking helps identify whether InMed Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

InMed Pharmaceuticals has shown inconsistent revenue, with total revenue dropping to 820,188 USD in Q2 2026, and a net income loss of -2,966,336 USD in Q3 2026. The gross margin has also decreased significantly to 15.97% in Q2 2026, indicating challenges in maintaining profitability.